Association between Antidepressants and Dementia Risk in Older Adults with Depression: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
Depression, commonly treated with antidepressants, is associated with an increased risk of dementia, especially in older adults. However, the association between antidepressant use and dementia risk is unclear. We searched for randomized controlled trials and observational studies from PubMed, Embase, and Cochrane on 1 February 2022, restricting to full texts in English. Since dementia is a chronic disease requiring a long induction time, we restricted studies with ≥1 year follow-up. We extracted the relative risk (RR) adjusted for the most variables from each study and evaluated the heterogeneity using I square (I2). The protocol was registered in the PROSPERO International Register of Systematic Reviews (CRD42022338038). We included six articles in the systematic review, of which the sample size ranged from 716 to 141,740, and the median length of follow-up was 5 years. The pooled RR was 1.21 (95% CI = 1.12–1.29) with an I2 of 71%. Our findings suggest that antidepressant use was associated with an increased risk of dementia in older adults with depression, yet moderate to high heterogeneity existed across studies. Future work accounting for the depression progression is needed to differentiate the effect of depression and antidepressants on dementia risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 The pooled estimates of the association between antidepressant use and the risk of dementia. The red dot indicates the point estimate of the risk ratio (RR), and the black line indicates the confidence interval (CI). The pooled RR was 1.21 (95% CI 1.12–1.29), indicating that the use of antidepressants was associated with an increased risk of dementia. The heterogeneity across the included studies was moderate to high (I2 = 71%) [36,37,38,39,40,41].](https://figures.cochat.ai/paper-figures/27bf3596a88e441db7e0ee6b34299bc5/association-between-antidepressants-and-dementia-risk-in-older-adults-with-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several systematic reviews and meta-analyses on the topic have also indicated that antidepressant use is associated with an increased risk of dementia. 6,20-22”
From Antidepressant exposure and long‐term dementia risk in a nationwide retrospective study on US veterans with midlife major depressive disorder (2024) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 2×
“When pooling results between articles, we used a random-effects model and reported the I square (I 2 ) to assess the extent of heterogeneity [34,35], considering the likelihood of heterogeneity between different articles.”
MethodPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“We used the latest version of the Cochrane risk-of-bias tool (RoB2) to evaluate the methodological quality of the included RCTs [30].”
MethodKok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., Abbafati, C., Adolph, C., Amlag, J. O., Aravkin, A. Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02143-7 · Cited by 5,444 · cited 1×
“It is estimated that 53 · 2 million additional cases of major depressive disorder were due to the COVID-19 pandemic globally [8].”
BackgroundBy the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15767 · Cited by 3,163 · cited 1×
“, amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, paroxetine, protriptyline, and trimipramine) among older adults with dementia or cognitive impairment [18].”
BackgroundPrevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“Dementia, a neurodegenerative disorder affecting 14% of adults aged 70 years or older [1], is characterized by a significant decline in memory, thinking, and the ability to perform daily activities [2].”
BackgroundEpidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Depression, a mood disorder that causes a persistent feeling of sadness and loss of interest [6], is also common, which occurs in one in five individuals throughout their lifetime [7] and dramatically increased after the COVID-19 pandemic.”
BackgroundBaumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660 · cited 1×
“depression can be a prodromal symptom or an early manifestation of dementia [12].”
BackgroundBehavioral and psychological symptoms of dementia
Cerejeira, J., Lagarto, L., & Mukaetova-Ladinska, E. B. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00073 · Cited by 1,425 · cited 1×
“Finally, patients with dementia can also develop depressive symptoms (i.e., neuropsychiatric symptoms of dementia) [13], of which the occurrence ranges from 30% to 50% [14].”
BackgroundPROSPERO: An International Register of Systematic Review Protocols
Schiavo, J. H. (2019) · Medical Reference Services Quarterly · doi:10.1080/02763869.2019.1588072 · Cited by 643 · cited 1×
“We prospectively registered the protocol in the PROSPERO International Register of Systematic Reviews (CRD42022338038) [29].”
MethodYaffe, K. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1481 · Cited by 445 · cited 1×
“Second, individuals with depression occurring prior to the age of 60 years have been associated with up to two-fold risk of developing subsequent dementia compared with those without depression before the age of 60 years [11].”
BackgroundOdds Ratios and Risk Ratios: What’s the Difference and Why Does It Matter?
Viera, A. J. (2008) · Southern Medical Journal · doi:10.1097/smj.0b013e31817a7ee4 · Cited by 347 · cited 1×
“HR is broadly equivalent to RR [32], and OR provides a reasonable approximation of RR in case-control studies and cohort studies in which the outcome occurs in less than 10% of the unexposed population [33].”
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329 · cited 4×
“Randomized controlled trials (RCTs) have reported cognitive improvement as a therapeutic benefit of SSRIs [20–25] and SNRIs [26].”
BackgroundInfluentialZubenko, G. S., Zubenko, W. N., McPherson, S., Spoor, E., Marin, D. B., Farlow, M. R., Smith, G. E., Geda, Y. E., Cummings, J. L., Petersen, R. C., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.857 · Cited by 314 · cited 1×
“Finally, patients with dementia can also develop depressive symptoms (i.e., neuropsychiatric symptoms of dementia) [13], of which the occurrence ranges from 30% to 50% [14].”
BackgroundDepression—an underrecognized target for prevention of dementia in Alzheimer’s disease
Dafsari, F. S., & Jessen, F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0839-1 · Cited by 312 · cited 2×
“…venlafaxine, moclobemide, and vortioxetine), a decrease in oxidative stress (e.g., fluoxetine and vortioxetine), a decrease in β -amyloid plaques (e.g., fluoxetine, citalopram, tranylcypromine, amitriptyline, and vortioxetine), and a decrease in tau aggregation (e.g., escitalopram) [42,45–47].”
BackgroundNyth, A. L., Gottfries, C. G., Lyby, K., Smedegaard‐Andersen, L., Gylding‐Sabroe, J., Kristensen, M., Refsum, H. ‐., Öfsti, E., Eriksson, S., & Syversen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03242.x · Cited by 258 · cited 1×
“Randomized controlled trials (RCTs) have reported cognitive improvement as a therapeutic benefit of SSRIs [20–25] and SNRIs [26].”
BackgroundAntidepressants for treating depression in dementia
Bains, J., Birks, J., & Dening, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944 · Cited by 214 · cited 4×
“Antidepres-sants are categorized into several classes based on different pharmacological mechanisms of action, with varied safety profiles [16].”
BackgroundInfluentialAntidepressants for treating depression in dementia
Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944.pub2 · Cited by 175
Odds ratio, hazard ratio and relative risk
Stare, J., & Maucort‐Boulch, D. (2021) · Advances in Methodology and Statistics · doi:10.51936/uwah2960 · Cited by 160 · cited 1×
“HR is broadly equivalent to RR [32], and OR provides a reasonable approximation of RR in case-control studies and cohort studies in which the outcome occurs in less than 10% of the unexposed population [33].”
The economic and societal burden of Alzheimer disease: managed care considerations
(2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89236 · Cited by 151 · cited 1×
“The global disease burden (GBD) of dementia has been increasing dramatically as life expectancy increases [3], with an estimated total lifetime cost of care for a patient with dementia of USD 412,936 in 2022 [4].”
BackgroundDoes Antidepressant Therapy Improve Cognition in Elderly Depressed Patients?
Doraiswamy, P. M., Krishnan, K. R. R., Oxman, T., Jenkyn, L. R., Coffey, D. J., Burt, T., & Clary, C. M. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.12.m1137 · Cited by 135
Cassano, G. B., Puca, F., Scapicchio, P. L., Trabucchi, M., & Italian Study Group on Depression in Elderly Patients (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0504 · Cited by 121
Wolf, N. J., & Hopko, D. R. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.04.004 · Cited by 116 · cited 1×
“Pharmacological therapies are primary interventions for depression [15].”
BackgroundWang, Y.-C., Tai, P.-A., Poly, T. N., Islam, M. M., Yang, H.-C., Wu, C.-C., & Li, Y.-C. (. (2018) · Behavioural Neurology · doi:10.1155/2018/5315098 · Cited by 115 · cited 4×
“The global disease burden (GBD) of dementia has been increasing dramatically as life expectancy increases [3], with an estimated total lifetime cost of care for a patient with dementia of USD 412,936 in 2022 [4].”
BackgroundInfluentialSelf-citationReboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00002 · Cited by 112
Cognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review
Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08609 · Cited by 107 · cited 1×
“For example, Keefe et al. conducted a systematic review of 43 RCTs to examine the effects of SSRIs, SNRIs, TCAs, and other psychotropic agents on cognitive function with a median follow-up duration of 8 weeks [44].”
BackgroundTorrisi, S. A., Geraci, F., Tropea, M. R., Grasso, M., Caruso, G., Fidilio, A., Musso, N., Sanfilippo, G., Tascedda, F., Palmeri, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00693 · Cited by 86
Geretsegger, C., Böhmer, F., & Ludwig, M. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199400910-00004 · Cited by 73
Cognitive Impairment in Depressed Older Adults: Implications for Prognosis and Treatment
Morimoto, S. S., Kanellopoulos, T., & Alexopoulos, G. S. (2014) · Psychiatric Annals · doi:10.3928/00485713-20140306-05 · Cited by 66 · cited 1×
“First, depression can impair cognitive function and result in “pseudodementia” [10].”
BackgroundDEVELOPMENT OF A QUANTITATIVE SCORING METHOD FOR STROBE CHECKLIST
Limaye, D., Limaye, V., Pitani, R. S., Fortwengel, G., Sydymanov, A., Otzipka, C., & Ziesenis, P. (2018) · Acta Poloniae Pharmaceutica - Drug Research · doi:10.32383/appdr/84804 · Cited by 66 · cited 2×
“For observational studies, we used the Strengthening the Reporting of Observational Studies in Epidemiology-Modified (STROBE-M) checklist to evaluate their quality [31].”
MethodInfluentialAntidepressant Treatment and Risk of Dementia: A Population-Based, Retrospective Case-Control Study
Lee, C. W.-S., Lin, C.-L., Sung, F.-C., Liang, J.-A., & Kao, C.-H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09580 · Cited by 61 · cited 1×
“Lee et al., 2016 [38] was a case-control study of excellent quality (STROBE-M: 0.92) conducted in Taiwan.”
InfluentialGoveas, J. S., Hogan, P. E., Kotchen, J. M., Smoller, J. W., Denburg, N. L., Manson, J. E., Tummala, A., Mysiw, W. J., Ockene, J. K., Woods, N. F., et al. (2012) · International Psychogeriatrics · doi:10.1017/s1041610211002778 · Cited by 54 · cited 2×
“The majority of the studies included both sexes, except one study (Goveas et al., 2012 [36]) that consisted of postmenopausal women only.”
BackgroundPharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task
Cassano, T., Calcagnini, S., Carbone, A., Bukke, V. N., Orkisz, S., Villani, R., Romano, A., Avolio, C., & Gaetani, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01067 · Cited by 50 · cited 1×
“, pathophysiological brain-derived the vulnerability of hippocampal atrophy, the deposition of β -amyloid plaques, and tau aggregation, which are the major neuropathological hallmarks of dementia [42,43].”
BackgroundCaruso, G., Grasso, M., Fidilio, A., Torrisi, S. A., Musso, N., Geraci, F., Tropea, M. R., Privitera, A., Tascedda, F., Puzzo, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.809541 · Cited by 49 · cited 1×
“…venlafaxine, moclobemide, and vortioxetine), a decrease in oxidative stress (e.g., fluoxetine and vortioxetine), a decrease in β -amyloid plaques (e.g., fluoxetine, citalopram, tranylcypromine, amitriptyline, and vortioxetine), and a decrease in tau aggregation (e.g., escitalopram) [42,45–47].”
BackgroundAssociation between anticholinergic burden and dementia in UK Biobank
Mur, J., Russ, T. C., Cox, S. R., Marioni, R. E., & Terrera, G. M. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12290 · Cited by 47 · cited 3×
“…Discussion This meta-analysis found that overall antidepressant use was associated with a higher long-term This may be explained by the anticholinergic side e ff ect of antidepressants, especially TCAs [16,17]. long-term ( ≥ 1-year follow-up) risk of dementia among older adults with depression.”
BackgroundCognitive effects of vortioxetine in older adults: a systematic review
Bishop, M. M., Fixen, D. R., Linnebur, S. A., & Pearson, S. M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211026796 · Cited by 39 · cited 1×
“Randomized controlled trials (RCTs) have reported cognitive improvement as a therapeutic benefit of SSRIs [20–25] and SNRIs [26].”
BackgroundChatterjee, S., Bali, V., Carnahan, R. M., Johnson, M. L., Chen, H., & Aparasu, R. R. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.12.011 · Cited by 38 · cited 3×
“Chatterjee et al., 2015 [37] was a nested case-control study of good quality (STROBE-M: 0.77) conducted in the US.”
BackgroundMethodResultInfluentialHeser, K., Luck, T., Röhr, S., Wiese, B., Kaduszkiewicz, H., Oey, A., Bickel, H., Mösch, E., Weyerer, S., Werle, J., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.016 · Cited by 38 · cited 1×
“…as potentially inappropriate medications (PIMs, i.e., imipramine, clomipramine, trimipramine, amitriptyline, doxepin, maprotiline, fluoxe-tine, tranylcypromine), were associated with an increased risk of dementia over 12 years of follow up [27], which was contrary to the results from RCTs.”
ResultAlboni, S., Benatti, C., Colliva, C., Radighieri, G., Blom, J. M. C., Brunello, N., & Tascedda, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603979 · Cited by 31
Su, J.-A., Chang, C.-C., Yang, Y.-H., Chen, K.-J., Li, Y.-P., & Lin, C.-Y. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120944152 · Cited by 22 · cited 1×
“Su et al., 2020 [41] was a retrospective cohort study of excellent quality (STROBE-M: 0.90) conducted in Taiwan.”
InfluentialPeakman, G., Karunatilake, N., Seynaeve, M., Perera, G., Aarsland, D., Stewart, R., & Mueller, C. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035147 · Cited by 21 · cited 1×
“Peakman et al., 2020 [40] was a retrospective cohort study of excellent quality (STROBE-M: 0.90) conducted in the UK.”
BackgroundInfluentialHan, F., Bonnett, T., Brenowitz, W. D., Teylan, M., Besser, L. M., Chen, Y., Chan, G., Cao, K., Gao, Y., & Zhou, X. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227924 · Cited by 14 · cited 1×
“Han et al., 2020 [39] was a retrospective cohort study of good quality (STROBE-M: 0.82) conducted in the US.”
BackgroundInfluential
Research works printed but not linked: 1
- Wiese, 2011, Geriatric depression: The use of antidepressants in the elderly, BC Med. J., 53, 341
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Dementia and depression: Biological connections with amyloid β protein
dos Santos, H. M., Bertollo, A. G., Mingoti, M. E. D., Grolli, R. E., Kreuz, K. M., & Ignácio, Z. M. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13996 · Cited by 26
“5 Therefore, depression appears as a risk factor for the development of dementia.”
BackgroundNelson, J. C., Gandelman, J. A., & Mackin, R. S. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.08.015 · Cited by 20
Biomarkers of cognitive and memory decline in psychotropic drug users
Grigore, M. M., Ruscu, M. A., Hermann, D. M., Colita, I.-C., Doeppner, T. R., Glăvan, D., & Popa‐Wagner, A. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02837-4 · Cited by 12
Ramos‐Cejudo, J., Corrigan, J. K., Zheng, C., Swinnerton, K. N., Jacobson, S. R., La, J., Betensky, R. A., Osorio, R. S., Madanes, S., Pomara, N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13853 · Cited by 11
Metadata
- Authors
- Wang, G. H.-M., Li, P., Wang, Y., Guo, J., Wilson, D. L., & Lo-Ciganic, W.-H.
- Affiliations
- University of Florida (US)
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2023-10-03
- Volume
- 12
- Issue
- 19
- Pages
- 6342
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC10573169
- OpenAlex
- W4387301669
- Cited by
- 23
- References
- 47
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 7
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- antidepressants, dementia risk, depression, older adults, drug safety, cognitive decline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.